Exploring TIL therapy \u0026 IO rechallenge in checkpoint refractory melanoma

(1:11)

IO Rechallenge: Uromigos Live 2024

(41:13)

CONTACT-03 and TiNivo-2: rethinking immunotherapy rechallenge in RCC

(1:21)

#UromigosLive24 RCC IO Rechallenge Panel Part 4: What About CTLA-4-Based Salvage After IO in RCC?

(11:58)

Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in GU Cancers

(7:6)

#UromigosLive24 RCC IO Rechallenge Panel Part 1: CONTACT-03, TiNivo-2 Study Results and Implications

(14:54)

#UromigosLive24 RCC IO Rechallenge Panel Pt 3: IO Therapy After Adjuvant Pembro?

(8:6)

Can we rechallenge immune checkpoint inhibitors (#ICI) as second-line treatment for advanced NSCLC?

(1:7)

#UromigosLive24 RCC IO Rechallenge Panel Pt 2: Do We Need a Post-Adjuvant Pembrolizumab Study?

(6:7)

Overview of 2nd line treatment options in advanced HCC

(14:53)

What is Rechallenge and Dechallenge

(1:6)

Managing renal cell carcinoma after progressing on checkpoint inhibitors

(2:14)

Investigating durable treatment strategies following progression in kidney cancer

(2:)

2nd line treatment in advanced HCC and when to switch

(26:19)

Emerging \u0026 Promising Clinical Trials in Ovarian Cancer: Learn the Latest

(24:52)

TiNiVO-2 Study ESMO 2024 - Re-challenging Patients with Immunotherapy

(4:5)

How to Treat Metastatic Non-Small Cell Lung Cancer w/o Targeted Mut in Front-line - Dr. Preeshagul

(25:28)